Brought to you by 
Follow-on nets $66mm for OmniPod developer Insulet
05 Nov 2009
Executive Summary
Insulet (developed the OmniPod insulin infusion system for diabetes management) netted $66mm through the public sale of 6.9mm common shares (including the overallotment) at $10.25 each.
Deal Industry
- Medical Devices
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Medical Devices
- Infusion Therapy Equipment and Supplies
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Follow-on nets $66mm for OmniPod developer Insulet
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice